NCT04428593View on ClinicalTrials.gov

Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 25, 2016

Primary Completion Date

November 21, 2016

Study Completion Date

November 21, 2016

Conditions
Metabolic Syndrome
Interventions
DRUG

Treamid 5 mg

The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.

DRUG

Treamid 15 mg

The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.

DRUG

Treamid 50 mg

The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.

DRUG

Placebo

The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.

All Listed Sponsors
lead

PHARMENTERPRISES LLC

INDUSTRY

NCT04428593 - Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers | Biotech Hunter | Biotech Hunter